Physician profile
Stephen Kaufman
NPI 1558421958
$1,926.74
in general payments reported to CMS, 2019-2025
9 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $13.60 · 2021: $98.67 · 2022: $179 · 2023: $147 · 2024: $537 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $897.89 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Dompe US, INC. | $330.06 | 2019-2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $250.00 | 2021-2024 | Tecnis Iol, Idesign Rs, Wavescan Wavefront System |
| Biotissue Holdings INC. | $179.05 | 2024-2025 | |
| Harrow Eye, LLC | $121.96 | 2025 | Vevye |
| Alcon Vision LLC | $54.55 | 2022-2024 | Clareon |
| Amgen INC. | $49.80 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $29.83 | 2022 | |
| Beaver-Visitec International, INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.